Fecal Microbiota Transplant for Recurrent C. diff: How FMT Works

  1. What FMT Is and Why It Works
  2. Success Rates for Recurrent CDI
  3. Donor Screening
  4. Delivery Methods
  5. FDA-Approved Microbiome Therapeutics
  6. Risks of FMT
  7. How to Access FMT
  8. When FMT Is Recommended
  9. Key Research Papers
  10. Featured Videos
  11. Connections

What FMT Is and Why It Works

Fecal microbiota transplant (FMT) is exactly what it sounds like: stool from a healthy, carefully screened donor is transferred into the gut of someone with recurrent Clostridioides difficile infection. The stool carries hundreds of bacterial species that together rebuild the recipient's depleted microbiome.

The reason this works so well comes down to a concept called colonization resistance. A healthy gut is crowded — trillions of bacteria compete for every available nutrient and surface. When that crowd is intact, C. diff spores that land in the colon find no room to germinate and multiply. Three specific mechanisms drive this resistance:

Antibiotics break colonization resistance by killing not only C. diff but also the very bacteria that normally suppress it. Each antibiotic course leaves the colon even more vulnerable than before, which is why recurrent CDI becomes a self-reinforcing cycle. FMT breaks that cycle by restoring the ecosystem rather than targeting C. diff directly.

Back to Table of Contents

Success Rates for Recurrent CDI

The efficacy data for FMT in recurrent CDI is among the most dramatic in modern gastroenterology. A landmark Dutch randomized trial published in The New England Journal of Medicine stopped early because FMT was so clearly superior to antibiotics that continuing the control arm was considered unethical.

Key numbers from clinical trials:

For context: fidaxomicin, the best antibiotic for recurrent CDI, achieves about 70% success in first recurrence but drops sharply with each subsequent episode. FMT not only outperforms every antibiotic regimen in multiply recurrent disease — it addresses the underlying cause (microbiome depletion) rather than just suppressing the pathogen temporarily.

Back to Table of Contents

Donor Screening

The safety of FMT depends entirely on the donor. A 2019 tragedy — two deaths from drug-resistant bacteria transmitted via FMT — demonstrated what happens when screening is inadequate (see the Risks section). Current screening protocols are far more stringent.

Infectious disease blood testing includes:

Stool testing includes:

Behavioral questionnaire: Recent international travel, antibiotic use within the prior 3 months, tattooing or body piercing within the prior 6 months, sexual risk factors, recreational drug use, and diet (donors eating high-risk foods may carry pathogens not covered by standard panels).

COVID-19 screening: Added during the pandemic; includes PCR testing and symptom questionnaire. The FDA issued a 2020 safety alert requiring COVID-19 screening after a patient on a clinical trial contracted COVID-19 via FMT.

Stool banks such as OpenBiome (the largest in the United States) and academic medical center programs maintain large pools of pre-screened, quarantined donors. Stool is quarantined for 60 days after collection while donor follow-up testing confirms no new infections — a critical step that the 2019 events showed was necessary.

Back to Table of Contents

Delivery Methods

There is no single "right" way to perform FMT. Four delivery routes are used in clinical practice and research, each with trade-offs.

Colonoscopy

The most commonly used method in landmark clinical trials. The gastroenterologist delivers donor material directly into the right colon (cecum and ascending colon) under direct visualization. Advantages: allows inspection of the colon, delivers material where colonization resistance is most important, longest track record. Disadvantages: requires bowel preparation, sedation, and a trained endoscopist — adding cost and patient burden.

Enema (Flexible Sigmoidoscopy or Rectal Instillation)

Material is delivered into the rectum and sigmoid colon via enema bag or flexible sigmoidoscope. Lower cost than colonoscopy and no sedation required, but material only reaches the left colon. Some studies show slightly lower initial success rates than colonoscopy, though differences are modest. Useful when colonoscopy is contraindicated.

Nasogastric or Nasoduodenal Tube

Material is delivered through a tube passed through the nose into the stomach or small intestine. Can be used in patients too ill to undergo colonoscopy or endoscopy under sedation. Main risk is aspiration — stomach content entering the lungs — making this route unsuitable for patients with swallowing problems or gastroparesis. Gastric acid also kills some bacteria, so upper-GI delivery may be slightly less effective.

Oral Capsules

Freeze-dried or frozen donor material is encased in enteric-coated capsules that dissolve in the small intestine, bypassing stomach acid. Patients swallow 24–40 capsules over one to two sessions. A pivotal Canadian randomized trial (Kao et al., 2017) found oral capsules non-inferior to colonoscopic FMT — roughly equivalent cure rates with substantially better patient acceptability. No sedation, no procedure room, no bowel prep. This route is now the basis for the FDA-approved product Vowst.

Back to Table of Contents

FDA-Approved Microbiome Therapeutics

For decades, FMT existed in a regulatory gray zone. The FDA classified it as a drug requiring an Investigational New Drug (IND) application, but enforcement was largely deferred for recurrent CDI because the clinical need was clear and no alternatives existed. In 2022 and 2023, the FDA approved the first two microbiome-based products for recurrent CDI — a landmark shift.

Rebyota (RBX2660) — Approved November 2022

Manufactured by Ferring Pharmaceuticals, Rebyota was the first FDA-approved FMT product. It is a broad-spectrum, donor-derived microbiome preparation given as a single 150 mL rectally administered dose. The pivotal PUNCH CD3 trial showed a statistically significant reduction in CDI recurrence versus placebo at 8 weeks. Rebyota is indicated for prevention of recurrent CDI in adults following antibiotic treatment for recurrent CDI.

Vowst (SER-109) — Approved April 2023

Manufactured by Seres Therapeutics, Vowst is an oral capsule product consisting of purified Firmicutes spores derived from healthy human donors. Rather than transferring the entire fecal microbiome, Vowst delivers a defined spore population that is particularly resistant to the harsh manufacturing process and to gastric acid. The ECOSPOR III trial (Feuerstadt et al., NEJM 2022) showed Vowst reduced CDI recurrence to 12% versus 40% for placebo at 8 weeks — a 70% relative risk reduction. Patients take 4 capsules daily for 3 days, starting 2–4 days after completing antibiotic therapy.

How These Differ from Traditional FMT

Traditional FMT transfers all living microorganisms in fresh or frozen donor stool, including bacteria, viruses, bacteriophages, fungi, and archaea. Rebyota preserves more of this diversity but is standardized and tested. Vowst is the most selective — purified spores only. The trade-off is that a narrower product may be slightly less potent in establishing broad colonization resistance, but it is also more consistent lot-to-lot and carries lower theoretical transmission risk. Both products require a physician prescription and are covered by many insurance plans for appropriately indicated patients.

Back to Table of Contents

Risks of FMT

FMT has an excellent safety record when performed at experienced centers with rigorous donor screening — but "excellent" does not mean "zero risk." Understanding the risks helps patients and families make informed decisions.

Transmission of Unknown Pathogens

Even comprehensive screening cannot detect every possible pathogen. Emerging viruses, novel drug-resistant organisms, and pathogens not yet characterized could theoretically be transmitted via donor stool. This theoretical risk motivates ongoing surveillance and research into pathogen-reduced or defined-composition products.

The 2019 Deaths — A Turning Point

In 2019, two immunocompromised patients in clinical trials died after receiving FMT from donors whose stool contained extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. The donors had not been screened for ESBL-producing organisms under the screening protocols in place at the time. The FDA issued a safety alert and required enhanced screening for drug-resistant organisms — the same screening now standard at all regulated programs. This tragedy led directly to the quarantine-and-retest protocols now used by stool banks.

COVID-19

In 2020, an immunocompromised patient on a clinical trial developed COVID-19 after receiving FMT prepared before the pandemic. The FDA promptly required donors to be screened for SARS-CoV-2 by PCR and symptom history. No further COVID-19 FMT transmissions have been reported since enhanced protocols were implemented.

Serious Adverse Events

In well-screened programs, serious adverse events are estimated at less than 0.1% of FMT procedures. Aspiration (inhaling gut material) is the main procedural risk with upper-GI delivery; colonoscopy carries standard endoscopy risks (perforation, bleeding) at the usual low rates.

Minor Side Effects

Common and short-lived: bloating, cramping, flatulence, and loose stools for 24–48 hours after the procedure. These reflect the sudden arrival of billions of new bacteria in the colon. Most patients find them mild and tolerable compared to ongoing CDI symptoms.

Long-Term Unknowns

Could the transplanted microbiome contribute to metabolic changes, weight gain, or other systemic effects years later? Long-term follow-up studies are reassuring so far, but this question is not fully answered. It is one reason researchers are interested in defined-composition products like Vowst rather than the entire fecal microbiome.

Back to Table of Contents

How to Access FMT

If you or a family member has had two or more CDI recurrences, here is how to navigate the current landscape.

Ask for a Gastroenterology Referral

Start with your primary care doctor or infectious disease specialist. Ask specifically for a referral to a gastroenterologist at an academic medical center or major hospital system that runs an FMT program. Not every GI practice performs FMT; community gastroenterologists may refer you to a specialized center.

Prescription FDA-Approved Products

Vowst and Rebyota are available by prescription from gastroenterologists. Coverage varies by insurer, but both manufacturers have patient assistance programs. Vowst is prescribed as 4 capsules daily × 3 days, taken at home. Rebyota requires a clinic visit for rectal administration.

Traditional FMT via Physician IND

The FDA currently classifies traditional FMT (stool preparation from a donor) as a drug that requires an IND application. Physicians at academic centers can hold an IND and perform FMT under that authorization. OpenBiome supplied prepared material to IND-holding physicians; as of 2023, OpenBiome has shifted focus to supporting clinical trials rather than routine clinical supply, so availability of traditional FMT outside of clinical trials is more limited than it was in 2018–2022.

Clinical Trials

Search ClinicalTrials.gov for "fecal microbiota transplant Clostridium difficile" to find enrolling studies. Clinical trial participation is often the best path to accessing traditional FMT and contributing to the research base.

Questions to Ask Your Doctor

Back to Table of Contents

FMT is not a first-line treatment for an initial CDI episode — it is reserved for patients whose infection keeps coming back despite antibiotics. The current guidelines are clear about this.

IDSA/SHEA 2021 Focused Update (Johnson et al., Clinical Infectious Diseases, 2021) recommends FMT:

FMT is not recommended for:

The timing matters too. Patients must complete their current antibiotic course and stop antibiotics 24–48 hours before FMT (or 2–4 days before starting Vowst) to give the new microbiome a chance to establish itself without being killed by residual antibiotic.

Back to Table of Contents

Key Research Papers

These are real published studies with verified PubMed IDs. The PMID links go directly to the paper abstract.

  1. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407–415. PMID 23323867 — The landmark Dutch RCT stopped early; colonoscopic FMT 81% vs vancomycin 31%.
  2. Cammarota G, Masucci L, Ianiro G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015;41(9):835–843. PMID 25728808
  3. Kelly CR, Khoruts A, Staley C, et al. Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent Clostridium difficile Infection: A Randomized Trial. Ann Intern Med. 2016;165(9):609–616. PMID 27547925
  4. Khanna S, Pardi DS, Kelly CR, et al. A novel microbiome therapeutic increases gut microbial diversity and prevents recurrent Clostridium difficile infection. J Infect Dis. 2016;214(2):173–181. PMID 26908744
  5. Feuerstadt P, Louie TJ, Lashner B, et al. SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile. N Engl J Med. 2022;386(3):220–229. PMID 35045228 — Pivotal trial for Vowst; 12% vs 40% recurrence rate at 8 weeks.
  6. DeFilipp Z, Bloom PP, Torres Soto M, et al. Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant. N Engl J Med. 2019;381(21):2043–2050. PMID 31665575 — The 2019 fatal transmission cases that prompted FDA enhanced screening requirements.
  7. Johnson S, Lavergne V, Skinner AM, et al. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis. 2021;73(5):e1029–e1044. PMID 34164374
  8. Seekatz AM, Young VB. Clostridium difficile and the microbiota. J Clin Invest. 2014;124(10):4182–4189. PMID 25036710 — Mechanistic review of colonization resistance and secondary bile acids.
  9. Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for Diagnosis, Treatment, and Prevention of Clostridium difficile Infections. Am J Gastroenterol. 2013;108(4):478–498. PMID 23439232
  10. Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017;389(10075):1218–1228. PMID 28214091 — FMT in IBD context; informs understanding of microbiome modulation for inflammatory gut disease.

PubMed searches for further reading:

  1. Fecal microbiota transplant Clostridioides difficile — PubMed
  2. SER-109 Vowst microbiome CDI — PubMed
  3. Colonization resistance secondary bile acids C. diff — PubMed

Back to Table of Contents

Connections

Back to Table of Contents